Proof of concept data were announced from an interim analysis of a phase 2 trial evaluating the efficacy and safety of LY-CoV555 for the treatment of symptomatic mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting. LY-CoV555 is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The investigational therapy is expected to block viral attachment and entry into human cells.

 

Credit: iStock, South_agency

Read more…